



Ind-Swift

Ref:ISLL:CH:2011:

Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



23rd March, 2011

To: All the Stock Exchanges

Sub: Pursuant to Clause 36 of the Listing Agreement.

Dear Sir,

Pursuant to clause 36 of the Listing Agreement, please find enclosed herewith a Press Release on the latest News Item of the Company for your information and record please.

Thanking you

Yours faithfully,

For **IND-SWIFT LABORATORIES LTD.**

**PARDEEP VERMA
COMPANY SECRETARY**

Encl: as above



Ind-Swift

Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



IND-SWIFT LABS FILES TWO MORE DMFS WITH USFDA

Ind-Swift Labs has received the USFDA nod for two more DMFs filed by it in US. The products for which the DMF acceptance from USFDA has been received are :

- 1. Temozolomide and**
- 2. Telmisartan**

Temozolomide is an Anti-Neoplastic drug with market size of US\$ 700 mns and Telmisartan is an Hypertension drug having market size of \$ 1.6 bn . Company has a strong basket of 40 plus products across 16 therapeutic segments.

The Company has so far filed 20 DMFs with USFDA and all of which have been approved . The company is already commercially supplying four molecules to the US market. **Speaking on the development Mr. N.R.Munjial Vice-Chairman and Managing Director of Ind-Swift laboratories Limited told that " Strategically Company is focussing on the US market for the Export of its products. The approval of these DMFs will enable the company to markets these products once the same goes off patent "**

The Company's wholly owned Subsidiary in US which is operational since 2005 is playing a significant role in establishing the business of the Company in the US market. The subsidiary has forged key contracts with leading generic companies in the US.

Company has state of the art Research and Development facility manned by over 100 scientists and with eight synthetic labs. The R&D is constantly focussing on development of new molecules and non-infringing processes for its products.

Mr. Munjal added that the company plans to file 4-5 DMFs every year in US in next 3-4 years.

The Company has recently received the PMDA, Japan approval for its manufacturing facilities. Earlier the Company had the USFDA, MHRA, TGA, COS , KFDA and Who-GMP approval for its facilities .

Ind Swift Laboratories Ltd (ISLL), with a clear focus on positioning itself as a primary supplier of specialized APIs to regulated markets. Hitherto focused on unregulated / soft regulated markets, ISLL has been steadily building a platform for a foray into regulated markets . ISLL has undertaken various Globalisation initiatives by entering in Regulated markets (US, Europe, Japan, Australia & Canada), registering its blockbuster products in various Non-Regulated & Soft Regulated countries, filing DMFs, investing heavily





Ind-Swift

Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



R&D, developing its IPR cell & upgrading manufacturing facilities with increased capacities to cater to the to cater to the increased global Demand for the Company's products.

Company has so far filed 302 DMFs with various regulatory authorities including 4 DMFs filed in Japan. Company has also filed 124 patents of which one for cardiovascular drug has been granted.

Company manufacturing facilities is spread over 42 acres of land area located a two different location Derabassi-Punjab and Jammu- J&K. The Company's Derabassi facility consists of 19 manufacturing blocks of which 11 are for manufacturing drugs for the regulated markets. The derabassi facility is approved by the USFDA, TGA, COS, KFDA and WHO GMP.

Company cloaked a turnover of Rs. 722.99 crores during the nine months of the financial year 2010-11 as against Rs 579.84 crore in corresponding nine months of FY 2009-10. Company earned a Net Profit of Rs 61.22 crores in nine months of FY 2010-11 against the Net Profit of Rs. 37.21 crores earned in nine months of the Financial year 2009-10.

About Ind Swift Laboratories Ltd


Ind Swift Laboratories (ISLL), a Global API player, is a part of the Ind - Swift group, headquartered in Chandigarh. The company was set up in 1995 as a Joint Venture between Ind swift Ltd. (ISL) and Punjab State Industrial Development Corporation (PSIDC), and commenced production in 1997.

In Feb 2003, ISL bought out PSIDC's 23.14% stake for a consideration of INR 82 mn (INR 32 / share), thus increasing it's holding in ISLL to 44%.

With FDA compliant plants located a two different locations and a robust product basket of 40 molecules (20 more in the pipeline), ISLL is well set to reap the rewards of its initiatives over the next few years, the time when US\$ 99 billion drugs goes off patent.

At the same time, growth rates have already started picking up, on the back of recent capacity additions and new product introductions, ISLL is expected to gather further momentum going forward – even before the commencement of its sales in the regulated markets.

ISLL is positioning itself as a primary supplier of APIs to generic players in regulated markets. The company already has a good presence in unregulated / soft regulated markets (exports products to over 50 countries) – it is now in agreement with global players for the supply of blockbuster drugs like *clarithromycin*, *atorvastatin*, *fexofenadine* & *clopidogrel* to regulated markets on patent expiry. The company also sells Specialised APIs and specialty





(A Recognised Export House)

ISLL has also started the process of regulatory filings – it has already filed 124 process patents with various authorities. Besides, as mentioned earlier, ISLL has filed over 302 DMFs in the US, Europe and other countries

